2nd Quarter - Report

ALKERMES, INC. for ALKERMES, INC.

Firm
Client
Income
—
Expenses
$940,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Maintain Medicare's six protected classes for depression and schizophrenia

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON New Deputy Chief of Staff/Legislative Director for Congressman Brett Guthrie (KY-02)
PETER NORMAN —
ABIGAIL PINKELE New Legislative Director for Rep. Gene Green from 2003-2012

Contacted: Office of Natl Drug Control Policy (NDCP); SENATE; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Executive Office of the President (EOP); Justice, Dept of (DOJ); Substance Abuse & Mental Health Services Administration (SAMHSA); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES

Health Issues HCR

Confronting the opioid and mental illness epidemic HR 1682 America Health Care Act of 2017, Coverage for the treatment of opioid dependence & serious mental illness H.R 1628, Better Care Reconciliation Act of 2017, Coverage for the treatment of opioid dependence & serious mental illness

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON New Deputy Chief of Staff/Legislative Director for Congressman Brett Guthrie (KY-02)
PETER NORMAN —
ABIGAIL PINKELE New Legislative Director for Rep. Gene Green from 2003-2012

Contacted: Justice, Dept of (DOJ); Substance Abuse & Mental Health Services Administration (SAMHSA); Veterans Affairs, Dept of (VA); Executive Office of the President (EOP); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Office of Natl Drug Control Policy (NDCP)

Bills named: H.R. 1682 (115th), H.R. 1628 (115th)

Pharmacy PHA

Public law #114-198, Cures Opioid Funding Implementation H.R. 2430 FDA Reauthorization Act of 2017 S.934 FDA Reauthorization Act of 2017

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON New Deputy Chief of Staff/Legislative Director for Congressman Brett Guthrie (KY-02)
PETER NORMAN —
ABIGAIL PINKELE New Legislative Director for Rep. Gene Green from 2003-2012

Contacted: SENATE; Natl Institutes of Health (NIH); Office of Natl Drug Control Policy (NDCP); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Substance Abuse & Mental Health Services Administration (SAMHSA); Justice, Dept of (DOJ)

Bills named: H.R. 2430 (115th), S. 934 (115th)

Alcohol and Drug Abuse ALC

Advance the use, and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act PL#115-31 Consolidated Appropriations Act of 2017 FY18 Appropriations Act H.R.2998 Military Construction, Veterans Affairs, & Related Agencies Appropriations Act of 2018 Ensure availability of all treatments for addiction in the Veterans Affairs and Indian Health Services, and through the Substance Abuse & Mental Health Services Administration. Advance use of addiction medicines in the Bureau of Prisons and within criminal justice funding (Byrne Jag)

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON New Deputy Chief of Staff/Legislative Director for Congressman Brett Guthrie (KY-02)
PETER NORMAN —
ABIGAIL PINKELE New Legislative Director for Rep. Gene Green from 2003-2012

Contacted: HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Office of Natl Drug Control Policy (NDCP); Justice, Dept of (DOJ); Natl Institutes of Health (NIH); Substance Abuse & Mental Health Services Administration (SAMHSA); Executive Office of the President (EOP); SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2998 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.